Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats

Journal of Neuroscience Research

Volumn 87, Issue 7, 2009, Pages 1645-1658

  Bishop, Christopher ^a   Krolewski, David M ^b   Eskow, Karen L ^a   Barnum, Christopher J ^a   Dupre, Kristin B ^a   Deak, Terrence ^a   Walker, Paul D ^b  

^a BINGHAMTON UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

c fos; L DOPA induced dyskinesia; Parkinson's disease; Preprodynorphin; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; LEVODOPA; MESSENGER RNA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PREPRODYNORPHIN; PROTEIN C FOS; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; CORPUS STRIATUM; DYSKINESIA; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INVOLUNTARY MOVEMENT; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSONISM; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DYNORPHINS; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; PIPERAZINES; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS C-FOS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RNA, MESSENGER; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 66049100759     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21978     Document Type: Article

References (72)

1. Ahlskog JE, Muenter MD. 2001. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448-458.
2. Andersson M, Konradi C, Cenci MA. 2001. cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. J Neurosci 21:9930-9943.
3. Antonelli T, Fuxe K, Tomasini MC, Bartoszyk GD, Seyfried CA, Tanganelli S, Ferraro L. 2005. Effects of sarizotan on the corticostriatal glutamate pathways. Synapse 58:193-199.
4. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, Barthe N, Bioulac BH, Gross CE, Fisone G, Bloch B, Bezard E. 2005. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 57:17-26.
5. Ba M, Kong M, Ma G, Yang H, Lu G, Chen S, Liu Z. 2007. Cellular and behavioral effects of 5-HT1A receptor agonist 8-OH-DPAT in a rat model of levodopa-induced motor complications. Brain Res 1127: 177-184.
6. Barnum CJ, Eskow KL, Dupre KB, Blandino P, Deak T, Bishop C. 2008. Exogenous corticosteroid reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1 beta. Neuroscience DOI:10.1016/j.neuroscience.2008.07.016.
7. Berke JD, Paletzki RF, Aronson GJ, Hyman SE, Gerfen CR. 1998. A complex program of striatal gene expression induced by dopaminergic stimulation. J Neurosci 18:5301-5310.
8. Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R. 2006. 5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis 23: 77-86.
9. Bibbiani F, Oh JD, Chase TN. 2001. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 57:1829-1834.
10. Bishop C, Taylor JL, Kuhn DM, Eskow KL, Park JY, Walker PD. 2006. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation. Eur J Neurosci 23:2669-2676.
11. Brotchie JM. 2005. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 20:919-931.
12. Carta M, Carlsson T, Kirik D, Bjorklund A. 2007. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130:1819-1833.
13. Cenci MA. 2007. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243.
14. Cenci MA, Lee CS, Bjorklund A. 1998. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694-2706.
15. Chang JW, Wachtel SR, Young D, Kang UJ. 1999. Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions. Neuroscience 88:617-628.
16. Chase TN. 1998. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 55 (Suppl 1):1-9.
17. Cho YH, Kim DS, Kim PG, Hwang YS, Cho MS, Moon SY, Kim DW, Chang JW. 2006. Dopamine neurons derived from embryonic stem cells efficiently induce behavioral recovery in a Parkinsonian rat model. Biochem Biophys Res Commun 341:6-12.
18. Christensson-Nylander I, Herrera-Marschitz M, Staines W, Hokfelt T, Terenius L, Ungerstedt U, Cuello C, Oertel WH, Goldstein M. 1986. Striato-nigral dynorphin and substance P pathways in the rat. I. Biochemical and immunohistochemical studies. Exp Brain Res 64: 169-192.
19. Dekundy A, Lundblad M, Danysz W, Cenci MA. 2007. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav Brain Res 179:76-89.
20. Dupre KB, Eskow KL, Negron G, Bishop C. 2007. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat. Brain Res 1158:135-143.
21. Dupre KB, Eskow KL, Barnum CJ, Bishop C. 2008a. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 55:1321-1328.
22. Dupre KB, Eskow KL, Steiniger A, Klioueva A, Negron G, Lormand L, Park JY, Bishop C. 2008b. Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat. Psychopharmacology 199:99-108.
23. Eskow KL, Gupta V, Alam S, Park JY, Bishop C. 2007. The partial 5-HT(1A) agonist buspirone reduces the expression and development of L-DOPA-induced dyskinesia in rats and improves L-DOPA efficacy. Pharmacol Biochem Behav 87:306-314.
24. Frechilla D, Cobreros A, Saldise L, Moratalla R, Insausti R, Luquin M, Del Rio J. 2001. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39:288-296.
25. Goetz CG, Damier P, Hicking C, Laska E, Muller T, Olanow CW, Rascol O, Russ H. 2007. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 22:179-186.
26. Guigoni C, Doudnikoff E, Li Q, Bloch B, Bezard E. 2007. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. Neurobiol Dis 26:452-463.
27. Hagell P, Widner H. 1999. Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale. Mov Disord 14:448-455.
28. Hjorth S, Sharp T. 1991. Effect of the 5-HT1A receptor agonist 8-OHDPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci 48:1779-1786.
29. Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P. 2006. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(1)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability. J Pharmacol Exp Ther 319:1225-1234.
30. Kannari K, Yamato H, Shen H, Tomiyama M, Suda T, Matsunaga M. 2001. Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation. J Neurochem 76:1346-1353.
31. Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M. 2002. Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease. No To Shinkei 54:133-137.
32. Kilpatrick IC, Jones MW, Phillipson OT. 1986. A semiautomated analysis method for catecholamines, indoleamines, and some prominent metabolites in microdissected regions of the nervous system: an isocratic HPLC technique employing coulometric detection and minimal sample preparation. J Neurochem 46:1865-1876.
33. Knobelman DA, Kung HF, Lucki I. 2000. Regulation of extracellular concentrations of 5 hydroxytryptamine (5-HT) in mouse striatum by 5-HT(1A) and 5-HT(1B) receptors. J Pharmacol Exp Ther 292:1111-1117.
34. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(2Delta Delta C(T)) method. Methods 25:402-408.
35. Lopez A, Munoz A, Guerra MJ, Labandeira-Garcia JL. 2001. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 103:639-651.
36. Luna-Munguia H, Manuel-Apolinar L, Rocha L, Meneses A. 2005. 5-HT1A receptor expression during memory formation. Psychopharmacology (Berl) 181:309-318.
37. Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. 2002. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 15:120-132.
38. Maeda T, Nagata K, Yoshida Y, Kannari K. 2005. Serotonergic hyper-innervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-DOPA. Brain Res 1046:230-233.
39. Matsubara K, Shimizu K, Suno M, Ogawa K, Awaya T, Yamada T, Noda T, Satomi M, Ohtaki KI, Chiba K, Tasaki Y, Shiono H. 2006. Tandospirone, a 5-HT1A agonist, ameliorates movement disorder via non-dopaminergic systems in rats with unilateral 6-hydroxydopamine-generated lesions. Brain Res 1112:126-133.
40. Melamed E, Ziv I, Djaldetti R. 2007. Management of motor complications in advanced Parkinson's disease. Mov Disord 22Suppl 17:S379-S384.
41. Mignon LJ, Wolf WA. 2005. 8-Hydroxy-2-(di-n-propylamino)tetralin reduces striatal glutamate in an animal model of Parkinson's disease. Neuroreport 16:699-703.
42. Mignon L, Wolf WA. 2007. Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson's disease. Psychopharmacology (Berl) 192:49-59.
43. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. 2006. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 29(Pt 4):1059-1069.
44. Mura A, Mintz M, Feldon J. 2002. Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system. Exp Neurol 177:252-264.
45. Obeso JA, Olanow CW, Nutt JG. 2000. Levodopa motor complications in Parkinson's disease. Trends Neurosci 23(10 Suppl):S2-S7.
46. Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H. 2004. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 27:58-62.
47. Olsson M, Nikkhah G, Bentlage C, Bjorklund A. 1995. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15(5 Pt 2):3863-3875.
48. Papapetropoulos S, Mash DC. 2007. Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. J Neural Transm 114:341-345.
49. Pasqualetti M, Nardi I, Ladinsky H, Marazziti D, Cassano GB. 1996. Comparative anatomical distribution of serotonin 1A, 1D alpha and 2A receptor mRNAs in human brain postmortem. Brain Res Mol Brain Res 39:223-233.
50. Pasqualetti M, Ori M, Castagna M, Marazziti D, Cassano GB, Nardi I. 1999. Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92:601-611.
51. Paul ML, Graybiel AM, David JC, Robertson HA. 1992. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J Neurosci 12:3729-3742.
52. Paxinos G, Watson W. 1998. The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press, p 1-456.
53. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001 29:e45.
54. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, Cenci MA, Calabresi P. 2003. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6:501-506.
55. Picconi B, Paille V, Ghiglieri V, Bagetta V, Barone I, Lindgren HS, Bernardi G, Angela CM, Calabresi P. 2008. L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol Dis 29:327-335.
56. Pisani A, Centonze D, Bernardi G, Calabresi P. 2005. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 20:395-402.
57. Putterman DB, Munhall AC, Kozell LB, Belknap JK, Johnson SW. 2007. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J Pharmacol Exp Ther 323:277-284.
58. Robertson GS, Herrera DG, Dragunow M, Robertson HA. 1989. L-DOPA activates c-fos in the striatum ipsilateral to a 6-hydroxydopamine lesion of the substantia nigra. Eur J Pharmacol 159:99-100.
59. Roy E, Cote PY, Gregoire L, Parent A, Bedard PJ. 1995. Mesencephalic grafts partially restore normal dynorphin levels in 6-hydroxydopamine-lesioned rats treated chronically with L-dihydroxyphenylalanine. Neuroscience 66:413-425.
60. Sagar SM, Sharp FR, Curran T. 1988. Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240:1328-1331.
61. 18F-labeled mefway, in rodents and imaging by PET in a nonhuman primate. J Nucl Med 47:1697-1706.
62. Sheng M, Greenberg ME. 1990. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 4:477-485.
63. Stocchi F, Nordera G, Marsden CD. 1997. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. Clin Neuropharmacol 20:95-115.
64. Svenningsson P, Gunne L, Andren PE. 2000. L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset. Neuroscience 99:457-468.
65. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. 1999. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10:631-634.
66. Taylor JL, Bishop C, Walker PD. 2005. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacol Biochem Behav 81:887-893.
67. Tintner R, Jankovic J. 2002. Treatment options for Parkinson's disease. Curr Opin Neurol 15:467-476.
68. Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M. 2005. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neurosci Res 52:185-194.
69. Tricklebank MD, Forler C, Fozard JR. 1984. The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106:271-282.
70. Winkler C, Kirik D, Bjorklund A, Cenci MA. 2002. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 10:165-186.
71. Yamamoto N, Soghomonian JJ. 2008. Time-course of SKF-81297-induced increase in glutamic acid decarboxylase 65 and 67 mRNA levels in striatonigral neurons and decrease in GABA(A) receptor alpha1 subunit mRNA levels in the substantia nigra pars reticulate, in adult rats with a unilateral 6-hydroxydopamine lesion. Neuroscience 154:1088-1099.
72. Yu H, Lewander T. 1997. Pharmacokinetic and pharmacodynamic studies of (R)-8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur Neuropsychopharmacol 7:165-172.